Bayer's New MRA Passes First TestBayer's New MRA Passes First Test

Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news